HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
19 Jul 2024
Historique:
received: 10 04 2024
accepted: 22 05 2024
medline: 19 7 2024
pubmed: 19 7 2024
entrez: 19 7 2024
Statut: aheadofprint

Résumé

Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care. Overall, 2386 HIV-1 protease/reverse transcriptase and 1831 integrase sequences from drug-naïve individuals diagnosed in north and central Italy between 2015 and 2021 were analysed. TDR was evaluated over time. Phylogeny was generated by maximum likelihood. Factors associated with TDR were evaluated by logistic regression. Individuals were mainly male (79.1%) and Italian (56.2%), with a median (IQR) age of 38 (30-48). Non-B infected individuals accounted for 44.6% (N = 1065) of the overall population and increased over time (2015-2021, from 42.1% to 51.0%, P = 0.002). TDR prevalence to any class was 8.0% (B subtype 9.5% versus non-B subtypes 6.1%, P = 0.002) and remained almost constant over time. Overall, 300 transmission clusters (TCs) involving 1155 (48.4%) individuals were identified, with a similar proportion in B and non-infected individuals (49.7% versus 46.8%, P = 0.148). A similar prevalence of TDR among individuals in TCs and those out of TCs was found (8.2% versus 7.8%, P = 0.707).By multivariable analysis, subtypes A, F, and CFR02_AG were negatively associated with TDR. No other factors, including being part of TCs, were significantly associated with TDR. Between 2015 and 2021, TDR prevalence in Italy was 8% and remained almost stable over time. Resistant strains were found circulating regardless of being in TCs, but less likely in non-B subtypes. These results highlight the importance of a continuous surveillance of newly diagnosed individuals for evidence of TDR to inform clinical practice.

Sections du résumé

BACKGROUND BACKGROUND
Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care.
METHODS METHODS
Overall, 2386 HIV-1 protease/reverse transcriptase and 1831 integrase sequences from drug-naïve individuals diagnosed in north and central Italy between 2015 and 2021 were analysed. TDR was evaluated over time. Phylogeny was generated by maximum likelihood. Factors associated with TDR were evaluated by logistic regression.
RESULTS RESULTS
Individuals were mainly male (79.1%) and Italian (56.2%), with a median (IQR) age of 38 (30-48). Non-B infected individuals accounted for 44.6% (N = 1065) of the overall population and increased over time (2015-2021, from 42.1% to 51.0%, P = 0.002). TDR prevalence to any class was 8.0% (B subtype 9.5% versus non-B subtypes 6.1%, P = 0.002) and remained almost constant over time. Overall, 300 transmission clusters (TCs) involving 1155 (48.4%) individuals were identified, with a similar proportion in B and non-infected individuals (49.7% versus 46.8%, P = 0.148). A similar prevalence of TDR among individuals in TCs and those out of TCs was found (8.2% versus 7.8%, P = 0.707).By multivariable analysis, subtypes A, F, and CFR02_AG were negatively associated with TDR. No other factors, including being part of TCs, were significantly associated with TDR.
CONCLUSIONS CONCLUSIONS
Between 2015 and 2021, TDR prevalence in Italy was 8% and remained almost stable over time. Resistant strains were found circulating regardless of being in TCs, but less likely in non-B subtypes. These results highlight the importance of a continuous surveillance of newly diagnosed individuals for evidence of TDR to inform clinical practice.

Identifiants

pubmed: 39028674
pii: 7717140
doi: 10.1093/jac/dkae189
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondazione Aviralia

Investigateurs

F Ceccherini-Silberstein (F)
M C Bellocchi (MC)
L Carioti (L)
M M Santoro (MM)
M Andreoni (M)
M Iannetta (M)
A Bertoli (A)
L Sarmati (L)
V Malagnino (V)
E Teti (E)
D Armenia (D)
A Antinori (A)
F Baldini (F)
R Bellagamba (R)
G Berno (G)
M Camici (M)
S Cicalini (S)
F De Zottis (F)
R Esvan (R)
L Fabeni (L)
F Forbici (F)
M Fusto (M)
R Gagliardini (R)
S Gebremeskel (S)
F Gili (F)
E Girardi (E)
E Grilli (E)
S Grisetti (S)
I Mastrorosa (I)
V Mazzotta (V)
A Mondi (A)
N Orchi (N)
S Ottou (S)
C Pinnetti (C)
S Pittalis (S)
D Pizzi (D)
M Plazzi (M)
A Vergori (A)
A R Buonomini (AR)
M Giuliani (M)
A Latini (A)
A Pacifici (A)
C F Perno (CF)
V Belvisi (V)
C Del Borgo (C)
A Carraro (A)
M Lichtner (M)
R Marocco (R)
V Borghi (V)
C Mussini (C)
W Gennari (W)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

Auteurs

Lavinia Fabeni (L)

Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Daniele Armenia (D)

Departmental Faculty, UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy.

Isabella Abbate (I)

Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Roberta Gagliardini (R)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Valentina Mazzotta (V)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Ada Bertoli (A)

Laboratory of Virology, Department of Laboratory Medicine, University Hospital Tor Vergata, Rome, Italy.

William Gennari (W)

Molecular Microbiology and Virology Unit, Department of Laboratory Medicine and Pathological Anatomy, Policlinic of Modena, University of Modena and Reggio Emilia, Modena, Italy.

Federica Forbici (F)

Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Giulia Berno (G)

Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Lorenzo Piermatteo (L)

Department of Biology, University of Rome Tor Vergata, Rome, Italy.

Vanni Borghi (V)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Carmela Pinnetti (C)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Alessandra Vergori (A)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Annalisa Mondi (A)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Giustino Parruti (G)

Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.

Fiorella Di Sora (F)

Unit of Clinical Immunology, San Giovanni Addolorata Hospital, Rome, Italy.

Marco Iannetta (M)

Department of Infectious Diseases, University Hospital Tor Vergata, Rome, Italy.

Miriam Lichtner (M)

Infectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, Polo Pontino, Latina, Italy.
Sant'Andrea Hospital, Clinical Infectious Diseases, Rome, Italy.

Alessandra Latini (A)

Sexually Transmitted Infection/Human Immunodeficiency Virus Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.

Cristina Mussini (C)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Loredana Sarmati (L)

Department of Infectious Diseases, University Hospital Tor Vergata, Rome, Italy.

Carlo Federico Perno (CF)

Microbiology and Diagnostic Immunology Unit, Department of Diagnostic and Laboratory Medicine, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy.

Enrico Girardi (E)

Scientific Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Andrea Antinori (A)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Francesca Ceccherini-Silberstein (F)

Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

Fabrizio Maggi (F)

Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

Maria Mercedes Santoro (MM)

Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

Classifications MeSH